B&K Corporation Limited is a biopharmaceutical company specializing in the research, development and commercialization of protein-based therapies, with a primary focus on wound healing treatments. The company’s core activities center on platelet-derived growth factor drugs targeting significant unmet medical needs such as thermal burns and diabetic foot ulcers, supported by a pipeline of multiple PDGF and other biologic candidates. B&K Corporation Limited has established protein/peptide and nucleic acid technology platforms to develop systematic and integrated biomacromolecule therapeutics. In addition to its biopharmaceutical pipeline, the company is also involved in related healthcare products, including medical devices and cosmetics, broadening its presence across the healthcare ecosystem. Operating within the biotechnology segment of the healthcare sector, B&K Corporation Limited plays a role in advancing innovative treatments aimed at improving tissue repair and regenerative outcomes in both acute and chronic wound settings.